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Abstract
Parkinson’s disease (PD) is the second most common neurodegenerative disorder of adult onset
in the United States. It is a debilitating condition and presents with both motor and non-motor
symptoms. Current treatment options are scarce and include replacement of dopamine
deficiency with levodopa which targets only motor symptoms of the disorder, does not halt its
progression, and is associated with side effects of its own, including dyskinesia. With medical
marijuana gaining popularity and being legalized in the United States, we examined the pros
and cons of marijuana in the treatment of Parkinson’s disease.
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Introduction And Background
Parkinson’s disease (PD) affects one to two per 1000 individuals, and its prevalence increases
with age, affecting 1% of the population above 60 years of age [1]. It is estimated that the
number of individuals with PD is expected to increase to nine million by 2030 in fifteen of the
most populous countries worldwide [2]. About 3% to 5% of the world’s population is known to
use marijuana, making it the most popular illicit substance [3].
In the United States, about 20 million people are marijuana users, estimated to 12.3% of its
total population, with about 1.2 million individuals using medical marijuana. As many as 23
states, as well as District of Columbia (DC), have legalized medical marijuana, and four states
have legalized its recreational use [3]. The use of marijuana has increased four times in
individuals aged 55 to 59 years and doubled among the elderly population aged 60 to 64 years,
between 2002 and 2012 [3]. Marijuana is widely used recreationally by older people to self-
medicate symptoms of neurological and psychiatric disorders such as PD, multiple sclerosis
(MS), amyotrophic lateral sclerosis, and schizophrenia [3]. About 44% of the population with PD
and MS is currently using marijuana [4]. 
Marijuana users report lower levels of disability compared to non-marijuana users [4]. In
addition to marijuana, there are various marijuana products composed of treatments such as
dronabinol, nabiximols, and nabilone that have been used in people with brain disorders [3].
The goal of this review article was to asses the pros and cons associated with the use of
marijuana for short-term or long-term purpose in patients with PD.
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Pathophysiology and treatment of Parkinson’s disease
PD arises as a result of the loss of dopaminergic neurons in the substantia nigra, resulting in
the loss of control of voluntary movements, which manifests as tremor, rigidity, and
bradykinesia [1]. Other non-motor symptoms are psychosis, cognitive impairment, depression,
and anxiety [3]. Its exact cause is unknown, with genetic and environmental factors playing a
role to some extent. Current treatment options for PD include activation of dopamine receptors
with levodopa, a biosynthetic precursor to dopamine. However, research has indicated that
levodopa is only valid during the early and intermediate stages of the disease and causes
irreversible dyskinesia in later stages [5]. It provides relief of motor symptoms of PD and does
not prevent its progression [2].
Mechanism of action of marijuana
Marijuana consists of 85 phytocannabinoids, from which cannabidiol (CBD) and
tetrahydrocannabinol (THC) are the main constituents [2]. CBD and THC are responsible for the
medicinal effects of marijuana [2]. CBD is non-psychoactive and is known to have hypnotic,
anxiolytic, antipsychotic, and neuroprotective effects [3]. THC is the main component
responsible for psychotropic effects of cannabis, and it acts via two types of G protein-coupled
receptors, known as cannabinoid type 1 (CB1) and type 2 (CB2) [6]. CB1 receptors are located
mainly in the central nervous system (CNS), and CB2 receptors reside in organs and cells of the
immune system [7]. The significant presence of cannabinoid receptors in the basal ganglia is
the reason behind the significance of cannabis or cannabinoids as possible pharmacotherapy for
treating PD and dyskinetic movement disorders [7]. 
While THC is psychoactive and a partial agonist to CB1 and CB2 receptors, CBD is indirectly
antagonistic to cannabinoid receptors and modulates the side effects of THC by increasing the
CB1-receptor density or some other CB1-mechanism [2]. CBD inhibits the psychotropic effects
of THC and improves its tolerability and therapeutic window [2], without being intoxicating [3].
Studies also suggest that cannabinoid antagonists exert anti-parkinsonism effects, while
agonists help with motor control [2].
Endocannabinoids are produced in the body and help regulate memory, pleasure,
concentration, thinking, movement, concentration, sensory and time perception, appetite, and
pain [2]. They act on CB1 and CB2 receptors [2]. The main endocannabinoids are anandamide
and 2-arachidonoyl glycerol [2]. Globus pallidus and substantia nigra are major brain areas
involved in the control of movements and contain the highest densities of CB1 receptors, as
well as the highest levels of endocannabinoids especially anandamide [2]. In a study involving
mice, loss of CB1 receptors resulted in decreased locomotor skills [7]. These findings support
the importance of the cannabinoids in the control of movement by the basal ganglia [7]. Studies
have proposed that dopaminergic D2 receptors regulate anandamide synthesis in the striatum
which gives inhibitory feedback to dopamine-induced motor activity [2]. It has been suggested
that activation of CB1 receptor neuro-protects against dopaminergic lesions and levodopa-
induced dyskinesia [2].
Pros of marijuana in Parkinson’s disease
Medical marijuana has been observed to improve both motor and non-motor symptoms
including bradykinesia, rigidity, tremor, sleep, and pain [2]. A study demonstrated the effects of
cannabis on 85 individuals with PD. Most of them consumed half a teaspoon of cannabis
leaves, along with their prescribed pharmacotherapy for PD. About 46% of these individuals
reported relief of PD symptoms in general, occurring at an average of 1.7 months after the first
use of marijuana, suggesting chronic use of marijuana may be required for improvement in
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symptoms. Bradykinesia was the most common symptom that was alleviated among cannabis
users, followed by muscle rigidity and tremor. Additionally, 14% of patients reported
improvement of levodopa-induced dyskinesia with the use of cannabis [7]. It was also noted
that higher urine levels (above 50 ng/ml) of a metabolite of THC in individuals using cannabis
for several months resulted in the visible improvement of bradykinesia and rigidity.
THC has shown to improve both activity and hand-eye coordination in an animal-PD model [3].
A clinical study of 22 patients with PD and smoking marijuana, resulted in improvement of
motor symptoms such as bradykinesia, resting tremor, rigidity, and posture, along with with
non-motor symptoms such as sleep and pain [3]. It has also been observed to improve rapid eye
movement (REM) sleep behavior disorder in individuals with PD [3]. Nabilone is a synthetic
cannabinoid receptor agonist, and when given with levodopa, it significantly reduces
dyskinesia and increases the duration of action of levodopa by 76% [2]. This is in contrast to
CB1 antagonist, Rimonabant, which did not produce improvement in motor symptoms in PD
[3].
Some people with PD have reported a ‘calming effect’ on their tremor and dyskinesia with the
use of marijuana [8]. Another study showed improvement of dyskinesia by up to 30% in PD
patients without worsening of symptoms, with CBD withdrawal causing dystonia [2]. A study
investigated the use of marijuana and compared it to non-marijuana users in individuals with
PD and MS. There was a lower level of disability in marijuana users as compared to non-users.
Memory, mood, and fatigue were other factors that cannabis had a positive effect on. About
85% of the patients reported effectiveness as moderate or higher due to improvement in
symptoms and no worsening with the use of cannabis [4].
Depression is a common symptom in PD, with a prevalence of up to 50%, that is undiagnosed
and undertreated [2]. Endocannabinoids are proposed to regulate mood and behavior, and their
loss can lead to depression [2]. It has been demonstrated in epidemiological studies that
marijuana users using marijuana daily or weekly exhibit a better mood as compared to non-
users, while other studies have shown an association between heavy use of marijuana and
depression, but it is unclear whether the depressive symptoms are due to marijuana or other
factors [2]. Hence, it is possible that the use of marijuana can help overcome depressive
symptoms in PD patients [2]. Also, marijuana has also been proposed to improve sleep, as
demonstrated in a clinical trial of 2000 patients with various pain disorders [2]. Studies have
further suggested that marijuana can help with spasticity and pain in people with PD and MS
and has neuroprotective effects [4]. In Colorado, a survey was conducted for PD patients, and its
findings were similar to past results of marijuana alleviating non-motor symptoms [2].
Marijuana not only improves motor and non-motor activities, but also has neuroprotective
properties, and helps in improving symptoms of PD as well as delaying its progression. Hence,
marijuana can be used as an alternative or add-on option in adults with PD to help improve the
overall quality of life patients suffering from PD [2].
Cons of marijuana in Parkinson’s disease
Adverse effects of marijuana include cognitive impairments, although this is temporary and
resolves with cessation of the drug. It is well known that marijuana can cause impairment in
working memory and may have a positive association with depression [4]. This is contradictory
to a study in which individuals with PD who were consuming marijuana had improved memory
and mood, which could be due to avoidance of the drug by individuals having problems with
memory or mood in fear of worsening of symptoms [4].
Weight gain is another possible side effect of marijuana, as the drug is thought to increase
caloric intake [4]. When initiated in adolescence, marijuana can contribute towards obesity but
an extensive study of adults demonstrated the lesser prevalence of obesity in marijuana users,
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and a recent survey of adults with PD and MS did not support obesity in marijuana users [4].
It is suggested that the acute use of marijuana can cause a transient motivational state in
marijuana non-users, and regular use prevents it [4]. It is also recommended that marijuana
negatively affects motor skills, but in a recent study in PD and MS patients, both users and
non-users spent the same amount of time on physical activity and sitting [4].
Short-term Effects of Marijuana
Acute marijuana use impairs consolidation, attention tasks, memory retrieval, verbal memory,
executive functions, and learning. Furthermore, frontal dysfunction has also been observed
which causes poor planning, decreased information processing speed, lack of self-monitoring,
poor planning, and changes in gross and fine motor skills [3].
Long-term Effects of Marijuana
Dependence is the primary concern after long-term use of marijuana. In the US, 10% of adults
use marijuana, and one-third of users suffer from abuse or dependence. Furthermore, 30% of
marijuana users and 50% to 95% of heavy users experience marijuana withdrawal symptoms.
One study followed participants from birth to age 38, and persistent marijuana users had six
point reduction in intelligence quotient (IQ) compared to non-users [5]. Chronic marijuana use
can result in dependence, cognitive impairments, depression, and anxiety, and increase the risk
for lung diseases [3].
Conclusions
PD is debilitating and can manifest as both motor and non-motor symptoms including
bradykinesia, resting tremor, rigidity, and depression. The current treatment provides a cure for
the motor symptoms, but only in the initial phase, and has side-effects of its own. Self-
medication with marijuana has improved many symptoms including bradykinesia, tremor,
rigidity, depression, sleep, and pain. However, the use of marijuana comes with short-term and
long-term effects including cognitive problems. It is observed that long-term use of marijuana
is needed for its result of taking place, which can also place an individual for risk of the
dependence of the illicit drug. More research is required to study the effects of marijuana in
patients with PD, for which treatment is limited.
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